Italia markets closed

UCB SA (UCB.BR)

Brussels - Brussels Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
96,64+0,50 (+0,52%)
Alla chiusura: 05:35PM CET

UCB SA

AllEe de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
http://www.ucb.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno7.600

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Jean-Christophe TellierCEO & Exec. DirectorN/DN/D1959
Ms. Kirsten Lund-JurgensenExec. VP of Supply & Technology SolutionsN/DN/D1959
Dr. Dhavalkumar D. Patel Ph.D., M.D.Exec. VP & Chief Scientific OfficerN/DN/D1961
Mr. William J. SilbeyExec. VP & Gen. CounselN/DN/D1959
Mr. Jean-Luc FleurialExec. VP & Chief HR OfficerN/DN/D1965
Prof. Iris Low-FriedrichChief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VPN/DN/D1960
Mr. Emmanuel CaeymaexExec. VP of Immunology Solutions & Head of USN/DN/D1969
Mr. Charl Van ZylExec. VP of Neurology Solutions & Head of EU/InternationalN/DN/D1967
Ms. Sandrine DufourExec. VP & CFON/DN/D1967
Ms. Caroline VancoillieChief Accounting Officer & CFO of Patient Value FunctionsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Governance aziendale

L'ISS Governance QualityScore di UCB SA al 26 settembre 2021 è 3. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 5; diritti degli azionisti: 1; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.